GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:GTXI
CUSIP40052B10
Phone901-523-9700
Debt
Debt-to-Equity RatioN/A
Current Ratio5.78%
Quick Ratio5.78%
Price-To-Earnings
Trailing P/E Ratio-9.85
Forward P/E Ratio-9.52
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.78 per share
Price / Book9.52
Profitability
EPS (Most Recent Fiscal Year)($1.75)
Net Income$-30,430,000.00
Net MarginsN/A
Return on Equity-113.27%
Return on Assets-90.41%
Miscellaneous
Employees27
Outstanding Shares21,850,000
GTX (NASDAQ:GTXI) Frequently Asked Questions
What is GTX's stock symbol?
GTX trades on the NASDAQ under the ticker symbol "GTXI."
How were GTX's earnings last quarter?
GTx Incorporated (NASDAQ:GTXI) announced its quarterly earnings results on Monday, March, 12th. The biopharmaceutical company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.05. View GTX's Earnings History.
When is GTX's next earnings date?
What price target have analysts set for GTXI?
2 brokers have issued twelve-month price targets for GTX's stock. Their predictions range from $30.00 to $45.00. On average, they expect GTX's stock price to reach $37.50 in the next year. View Analyst Ratings for GTX.
Who are some of GTX's key competitors?
Some companies that are related to GTX include Radius Health (RDUS), Impax Laboratories (IPXL), Pacira Pharmaceuticals (PCRX), Zogenix (ZGNX), Immuron (IMRN), ImmunoGen (IMGN), G1 Therapeutics (GTHX), Myovant Sciences (MYOV), WAVE Life Sciences (WVE), Theravance Biopharma (TBPH), Endo International (ENDP), TherapeuticsMD (TXMD), PTC Therapeutics (PTCT), Apellis Pharmaceuticals (APLS) and Dynavax Technologies (DVAX).
Who are GTX's key executives?
GTX's management team includes the folowing people:
- Dr. Robert James Wills, Exec. Chairman (Age 64)
- Mr. Marc S. Hanover, Co-Founder, CEO & Director (Age 55)
- Mr. Henry P. Doggrell, VP, Chief Legal Officer, Gen. Counsel & Sec. (Age 69)
- Mr. Jason T. Shackelford, VP of Fin. & Accounting, Principal Financial & Accounting Officer and Corp. Controller (Age 43)
- Dr. Diane C. Young M.D., Chief Medical Officer and VP (Age 61)
Has GTX been receiving favorable news coverage?
News headlines about GTXI stock have trended somewhat positive recently, Accern reports. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. GTX earned a media sentiment score of 0.10 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 44.95 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of GTX?
Shares of GTXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GTX's stock price today?
One share of GTXI stock can currently be purchased for approximately $16.95.
How big of a company is GTX?
GTX has a market capitalization of $380.06 million. The biopharmaceutical company earns $-30,430,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. GTX employs 27 workers across the globe.
How can I contact GTX?
GTX's mailing address is 175 TOYOTA PLAZA 7TH FLOOR, MEMPHIS TN, 38103. The biopharmaceutical company can be reached via phone at 901-523-9700 or via email at [email protected]
MarketBeat Community Rating for GTX (GTXI)
MarketBeat's community ratings are surveys of what our community members think about GTX and other stocks. Vote "Outperform" if you believe GTXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
GTX (NASDAQ:GTXI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for GTX in the last 12 months. Their average twelve-month price target is $37.50, suggesting that the stock has a possible upside of 121.24%. The high price target for GTXI is $45.00 and the low price target for GTXI is $30.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | N/A |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $37.50 | $37.50 | $17.00 | N/A |
| Price Target Upside: | 121.24% upside | 79.60% upside | 52.88% upside | N/A |
GTX (NASDAQ:GTXI) Consensus Price Target History
GTX (NASDAQ:GTXI) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
GTX (NASDAQ:GTXI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
GTX (NASDAQ GTXI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 40.90%
Institutional Ownership Percentage: 12.71%
GTX (NASDAQ GTXI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/5/2018 | Henry Patton Doggrell | VP | Sell | 4,965 | $11.33 | $56,253.45 | 54,804 |  |
| 1/5/2018 | Jason T Shackelford | Insider | Sell | 3,090 | $11.33 | $35,009.70 | 31,111 | |
| 1/5/2018 | Marc Steven Hanover | CEO | Sell | 7,309 | $11.33 | $82,810.97 | 129,990 | |
| 10/14/2016 | Peak Foundation Pyramid | Major Shareholder | Buy | 7,716,049 | $0.81 | $6,249,999.69 | 38,249,528 | |
| 6/16/2016 | Robert James Wills | Chairman | Buy | 100,000 | $0.65 | $65,000.00 | 1,200,000 | |
| 3/1/2016 | J Kenneth Glass | Director | Buy | 44,000 | $0.60 | $26,400.00 | 183,768 | |
| 1/26/2016 | Marc Steven Hanover | CEO | Buy | 4,000 | $0.65 | $2,600.00 | 1,257,224 | |
| 1/25/2016 | Marc Steven Hanover | CEO | Buy | 12,813 | $0.63 | $8,072.19 | 1,253,224 | |
| 1/19/2016 | Marc Steven Hanover | CEO | Buy | 25,000 | $0.50 | $12,500.00 | 1,240,411 | |
| 1/14/2016 | Marc Steven Hanover | CEO | Buy | 25,000 | $0.49 | $12,250.00 | 1,193,311 | |
| 12/24/2015 | J Kenneth Glass | Director | Buy | 100 | $0.79 | $79.00 | 139,768 | |
| 12/22/2015 | J Kenneth Glass | Director | Buy | 1,907 | $0.78 | $1,487.46 | 139,068 | |
| 12/21/2015 | J Kenneth Glass | Director | Buy | 39,900 | $0.78 | $31,122.00 | 137,761 | |
| 5/19/2015 | J Kenneth Glass | Director | Buy | 24,500 | $1.25 | $30,625.00 | | |
| 5/14/2015 | Robert James Wills | Chairman | Buy | 46,140 | $0.96 | $44,294.40 | | |
| 5/8/2015 | Henry Patton Doggrell | VP | Buy | 25,477 | $0.80 | $20,381.60 | | |
| 5/8/2015 | Robert James Wills | Chairman | Buy | 50,000 | $0.80 | $40,000.00 | | |
| 4/22/2015 | J Kenneth Glass | Director | Buy | 10,000 | $0.72 | $7,200.00 | | |
| 4/21/2015 | J Kenneth Glass | Director | Buy | 11,608 | $0.71 | $8,241.68 | | |
| 4/15/2015 | J Kenneth Glass | Director | Buy | 3,300 | $0.72 | $2,376.00 | | |
| 4/10/2015 | J Kenneth Glass | Director | Buy | 16,400 | $0.67 | $10,988.00 | | |
| 9/23/2014 | Marc Steven Hanover | CEO | Buy | 5,000 | $0.75 | $3,750.00 | | |
| 9/17/2014 | Marc Steven Hanover | CEO | Buy | 10,000 | $0.74 | $7,400.00 | | |
| 8/21/2014 | Marc Steven Hanover | CEO | Buy | 20,000 | $1.00 | $20,000.00 | | |
| 8/19/2014 | Marc Steven Hanover | CEO | Buy | 10,000 | $1.01 | $10,100.00 | | |
| 8/8/2014 | Henry Patton Doggrell | VP | Buy | 10,000 | $0.97 | $9,700.00 | | |
| 8/8/2014 | Marc Steven Hanover | CEO | Buy | 30,000 | $0.93 | $27,900.00 | | |
| 8/7/2014 | Jason T Shackelford | Insider | Buy | 10,000 | $0.92 | $9,200.00 | | |
| 8/7/2014 | Marc Steven Hanover | CEO | Buy | 30,000 | $0.92 | $27,600.00 | | |
| 6/6/2014 | James T Dalton | VP | Sell | 72,883 | $1.30 | $94,747.90 | | |
| 3/21/2014 | Jack Schuler | major shareholder | Sell | 1,192,251 | $1.84 | $2,193,741.84 | 6,165,261 | |
| 8/22/2013 | Jack Schuler | major shareholder | Buy | 93,777 | $1.36 | $127,536.72 | 7,357,512 | |
| 8/21/2013 | Jack Schuler | major shareholder | Buy | 309,591 | $1.42 | $439,619.22 | 7,263,735 | |
| 7/9/2013 | Mark Edward Mosteller | CFO | Sell | 17,000 | $6.99 | $118,830.00 | | |
| 1/17/2013 | James T Dalton | VP | Sell | 20,000 | $5.20 | $104,000.00 | | |
| 12/14/2012 | Timothy R G Sear | Director | Buy | 50,000 | $4.33 | $216,500.00 | | |
| 8/27/2012 | J Kenneth Glass | Director | Buy | 10,000 | $3.76 | $37,600.00 | | |
(Data available from 1/1/2013 forward)
GTX (NASDAQ GTXI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | GTX (GTXI) Lowered to Hold at BidaskClub
www.americanbankingnews.com - April 17 at 9:57 AM |
 | BRIEF-Gtx To Present Phase 2 Enobosarm Clinical Trial Results In Stress Urinary Incontinence
www.reuters.com - April 17 at 9:30 AM |
| Zacks: Analysts Set $37.50 Price Target for GTx Incorporated (GTXI)
www.americanbankingnews.com - April 16 at 7:25 PM |
 | GTx to Present Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at a Podium Presentation at 2018 AUA Annual Meeting
finance.yahoo.com - April 16 at 9:03 AM |
| Ra Pharmaceuticals (RARX) vs. GTX (GTXI) Head-To-Head Comparison
www.americanbankingnews.com - April 14 at 9:33 AM |
| Research Report Identifies Third Point Reinsurance, GTx, pdvWireless, ACM Research, Reading International, and Canadian National Railway with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
finance.yahoo.com - April 13 at 9:25 AM |
| Brokerages Expect GTx Incorporated (GTXI) to Announce -$0.43 Earnings Per Share
www.americanbankingnews.com - April 11 at 11:16 PM |
 | Active-Investors: Blog Exposure - GTx Completed Patient Enrollment Several Months Ahead in the Phase-2 Clinical Trial of Enobosarm in SUI
www.finanznachrichten.de - April 11 at 9:44 AM |
 | The Medical Report: Saint Francis promotes new COO; GTx study aims to fix leaks
www.bizjournals.com - April 9 at 4:40 PM |
 | GTx completes patient enrollment in a Phase 2 clinical trial of enobosarm in SUI
seekingalpha.com - April 9 at 9:21 AM |
| GTx Announces Early Completion of Patient Enrollment in the ASTRID Trial, a Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence
finance.yahoo.com - April 9 at 9:21 AM |
| GTX (GTXI) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 3:00 PM |
| GTX (GTXI) Now Covered by Stifel Nicolaus
www.americanbankingnews.com - March 31 at 8:16 PM |
| GTX (GTXI) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 8:30 PM |
 | Xiaomi’s Mi Gaming Laptop comes with Nvidia GTX 1060 graphics and costs $1,430
www.msn.com - March 29 at 9:28 AM |
| GTX (GTXI) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - March 27 at 10:56 PM |
| Xiaomi unveils a gaming laptop with Kaby Lake CPU, NVIDIA GTX 1060, and RGB lighting
www.msn.com - March 27 at 9:33 AM |
| Zacks: Analysts Expect GTx Incorporated (GTXI) to Post -$0.43 EPS
www.americanbankingnews.com - March 25 at 11:12 PM |
| GTX (GTXI) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 25 at 11:22 AM |
| GTX (GTXI) Given "Buy" Rating at Robert W. Baird
www.americanbankingnews.com - March 24 at 12:10 PM |
| GTX (GTXI) Lowered to Buy at BidaskClub
www.americanbankingnews.com - March 22 at 12:56 AM |
| Analysts Set $37.50 Price Target for GTx, Inc. (GTXI)
www.americanbankingnews.com - March 17 at 1:43 PM |
| GTX's (GTXI) "Buy" Rating Reiterated at Robert W. Baird
www.americanbankingnews.com - March 15 at 3:02 PM |
| Report: Developing Opportunities within Odonate Therapeutics, Greenlight Reinsurance, Landmark Infrastructure Partners LP, GTx, First Mid-Illinois Bancshares, and iClick Interactive Asia Group — Future Expectations, Projections Moving into 2018
finance.yahoo.com - March 15 at 9:02 AM |
| GTX (GTXI) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 13 at 10:39 AM |
| GTx reports 4Q loss
finance.yahoo.com - March 12 at 5:47 PM |
| GTx Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 12 at 5:47 PM |
| Zacks: GTx, Inc. (GTXI) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - March 7 at 3:28 PM |
| GTX (GTXI) to Release Earnings on Tuesday
www.americanbankingnews.com - March 6 at 2:32 AM |
| GTx, Inc. (GTXI) Soars 25% in Light of Encouraging Data in SUI
finance.yahoo.com - March 5 at 5:15 PM |
| Why Square, CF Industries Holdings, and GTx Jumped Today
finance.yahoo.com - March 5 at 5:15 PM |
| GTx shares surge 30% on incontinence trial results
finance.yahoo.com - March 5 at 5:15 PM |
| GTX (GTXI) PT Raised to $45.00 at Stifel Nicolaus
www.americanbankingnews.com - March 5 at 1:58 PM |
| GTx Announced New Data Demonstrating Enobosarm’s Potential to Treat Stress Urinary Incontinence at SUFU 2018
finance.yahoo.com - March 5 at 9:16 AM |
| GTX (GTXI) Lifted to Strong-Buy at BidaskClub
www.americanbankingnews.com - February 25 at 5:28 PM |
| Reviewing Corvus Pharmaceuticals (CRVS) & GTX (GTXI)
www.americanbankingnews.com - February 22 at 11:12 PM |
| GTx Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence Accepted for Podium Presentation at SUFU
finance.yahoo.com - February 22 at 5:02 PM |
| Zacks: GTx, Inc. (GTXI) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - February 20 at 5:32 PM |
| BidaskClub Lowers GTX (GTXI) to Buy
www.americanbankingnews.com - February 18 at 2:40 PM |
| Zacks: Analysts Set $16.50 Price Target for GTx, Inc. (GTXI)
www.americanbankingnews.com - February 8 at 7:20 PM |
| Contrasting SAGE Therapeutics (SAGE) and GTX (GTXI)
www.americanbankingnews.com - January 30 at 3:20 PM |
| BidaskClub Upgrades GTX (GTXI) to Strong-Buy
www.americanbankingnews.com - January 27 at 3:24 PM |
| Zacks: Brokerages Anticipate GTx, Inc. (GTXI) Will Post Earnings of -$0.39 Per Share
www.americanbankingnews.com - January 17 at 3:12 AM |
| Jason T. Shackelford Sells 3,090 Shares of GTx, Inc. (GTXI) Stock
www.americanbankingnews.com - January 9 at 7:56 PM |
| GTx, Inc. (GTXI) VP Sells $56,253.45 in Stock
www.americanbankingnews.com - January 9 at 7:16 PM |
| GTx, Inc. (GTXI) CEO Sells $82,810.97 in Stock
www.americanbankingnews.com - January 9 at 7:16 PM |
| Analysts Expect GTx, Inc. (GTXI) to Post ($0.39) EPS
www.americanbankingnews.com - January 8 at 9:40 AM |
| BRIEF-GTX Inc Files For Mixed Shelf Offering Of Up To $150 Mln
www.reuters.com - December 23 at 9:19 PM |
| GTx, Inc. (GTXI) Receives Consensus Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - December 23 at 11:40 AM |
| -$0.39 Earnings Per Share Expected for GTx, Inc. (GTXI) This Quarter
www.americanbankingnews.com - December 14 at 7:16 AM |
GTX (NASDAQ:GTXI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
GTX (NASDAQ:GTXI) Income Statement, Balance Sheet and Cash Flow Statement
GTX (NASDAQ GTXI) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
